Krystal Biotech (KRYS) Change in Accured Expenses (2016 - 2026)

Krystal Biotech has reported Change in Accured Expenses for 11 years, with the latest figure at $5.4 million in Q2 2026.

• Change in Accured Expenses for Q2 2026 came in at $5.4 million, up 520.25% year-over-year; the trailing twelve-month figure through Jun 2026 was $10.8 million (down 8.43% YoY), and the FY2025 annual result was $14.1 million, up 161.62% from the prior year.
• Change in Accured Expenses advanced to $5.4 million in Q2 2026, from -$6.3 million in the prior quarter.
• Over five years, Change in Accured Expenses peaked at $7.5 million in Q4 2024 and troughed at -$6.3 million in Q1 2026.
• A 5-year average of $1.6 million and a median of $2.0 million in 2022 frame the typical range for Change in Accured Expenses.
• The widest annual swing landed in 2022, when Change in Accured Expenses soared 629.35%; it then sank 272.03% in 2023.
• A 5-year view of Change in Accured Expenses shows it stood at $2.2 million in 2022, then surged by 70.75% to $3.7 million in 2023, then jumped by 103.18% to $7.5 million in 2024, then slipped by 22.68% to $5.8 million in 2025, then fell by 6.01% to $5.4 million in 2026.
• Per Business Quant data, the three most recent Change in Accured Expenses figures were $5.4 million in Q2 2026, -$6.3 million in Q1 2026, and $5.8 million in Q4 2025.